Business ❯ Healthcare

Pharmaceuticals

Drug Development Clinical Trials Weight Loss Drugs Market Competition Drug Pricing Biotechnology Acquisitions Manufacturing Oncology Market Trends

Samsung Biologics to Acquire GSK’s Human Genome Sciences Rockville Manufacturing Site for $280 Million

Closing is slated for late Q1 2026, positioning the facility to join Samsung’s global CDMO network.

Jan. 16 Deadline Nears in Skye Bioscience Investor Class Actions

Lilly’s Triple-Agonist Retatrutide Shows Major Phase 3 Weight Loss as Grey-Market Use Prompts Warning

Sanofi Secures Global Rights to ADEL’s Alzheimer’s Antibody in Deal Worth Up to $1.04 Billion

Cencora to Buy TPG’s Stake in OneOncology in $5 Billion Deal

Canopy Growth Jumps as Reports Say Trump May Pursue Federal Cannabis Rescheduling

Law Firms Urge Telix Investors To Seek Lead Role by Jan. 9 in Securities Class Action

HSBC Upgrades AbbVie to Buy, Lifts Target to $265 as Skyrizi and Rinvoq Drive Growth

Zealand Pharma Unveils ‘Metabolic Frontier 2030’ With Targets for Five Launches

CVS Lifts 2025 Outlook, Sets 2026 Targets and Unveils AI Consumer Platform

Race for Lead Plaintiff in aTyr Securities Case Nears Dec. 8 Deadline After Phase 3 Trial Failure

FDA Meeting Minutes Undercut uniQure’s Plan to File Huntington’s Gene Therapy for Approval

Bristol Myers Delays ADEPT-2 Alzheimer’s Psychosis Readout to 2026 After Site Irregularities

aTyr Investors Face Dec. 8 Deadline in Securities Suits Over Efzofitimod Trial Failure

MoonLake Investors Face Dec. 15 Lead-Plaintiff Deadline in Securities Class Action

Novo Nordisk Files for 7.2 mg Wegovy Dose After Stronger Weight-Loss Results

Telix Hit With Securities Class Action Over Prostate-Drug Claims and Supply Chain Assurances

Eli Lilly Briefly Hits $1 Trillion as GLP-1 Boom Spurs Fresh Analyst Targets

Embecta Beats Q4 EPS Expectations as Sales Miss and Debt Declines

Skye Bioscience Hit With Securities Class Action Over Nimacimab Disclosures as Firms Court Lead Plaintiff